Vestal Point Capital’s Immunome IMNM Stock Holding History

Vestal Point Capital’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,000,000	Closed	-$12.1M	–	79
2024 Q2	$12.1M	Buy	+1,000,000	New	+$15.6M	0.9%	32

Other funds holding IMNM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Vestal Point Capital's IMNM Position: Q3 2024 in Review

Vestal Point Capital sold out of Immunome (IMNM) in Q3 2024, closing a stake of 1,000,000 shares — an estimated $12.1M sold.

Vestal Point Capital first reported a position in IMNM in Q2 2024 and held it in 1 quarter. The position peaked at $12.1M in Q2 2024. 115 funds tracked by Wall St. Rank hold IMNM as of Q3 2024.

Vestal Point Capital reported no remaining Immunome position as of Q3 2024 after selling out during the quarter.
Vestal Point Capital sold 1,000,000 Immunome shares in Q3 2024, an estimated $12.1M.
Vestal Point Capital first reported a position in Immunome in Q2 2024 and held it in 1 quarter.
Vestal Point Capital's Immunome position peaked at $12.1M in Q2 2024.
115 funds tracked by Wall St. Rank held Immunome as of Q3 2024.

Based on Vestal Point Capital's 13F filing for Q3 2024, filed 14 Nov 2024.